We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Galantamine Bioequivalence Study of Dr. Reddy's Under Fed Condition

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01372306
First Posted: June 13, 2011
Last Update Posted: June 30, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Dr. Reddy's Laboratories Limited
  Purpose
Galantamine Hydrobromide Tablets, Bioequivalence study of Dr. Reddy's under Fed condition.

Condition Intervention Phase
Fed Drug: Reminyl Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, Ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers Under Fed Conditions

Resource links provided by NLM:


Further study details as provided by Dr. Reddy's Laboratories Limited:

Primary Outcome Measures:
  • Bioequivalence on Cmax and AUC parameters [ Time Frame: 2 months ]

Enrollment: 24
Study Start Date: October 2004
Study Completion Date: November 2004
Primary Completion Date: November 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Galantamine
Galantamine Hydrobromide Tablets of Dr. Reddy's
Drug: Reminyl
Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Other Name: Reminyl 4 mg
Active Comparator: Reminyl
Reminyl 4 mg tablets of Janssen Pharmaceutical Products
Drug: Reminyl
Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
Other Name: Reminyl 4 mg

Detailed Description:
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr.Reddy's Laboratories, ltd. and Janssen Pharmaceutical Products, l.P. (Reminyl®)4 mg Galantamine HBr Tablets in Healthy Adult Male Volunteers under Fed Conditions
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subject candidates must fulfill all of the following inclusion criteria to be eligible for participation in the studyI unless otherwise specified:

  • Healthy adult male volunteers, 18-55 years of age;
  • Weighing at least 60 kg and within 15% of their ideal weights (Table of "Desirable Weights of Adults", Metropolitan Ufe Insurance Company, 1983);
  • Medically healthy subjects with clinically normal laboratory profiles, vital signs and ECGs;
  • Give voluntary written informed consent to participate in the study.

Exclusion Criteria:

Subject candidates must not be enrolled in the stUdy if they meet any of the following criteria:

  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease.
  • In addition, history or presence of:
  • alcoholism or drug abuse within the past year;
  • hypersensitivity or idiosyncratic reaction to galantamine or other anticholinesterase inhibitors;
  • asthma and seizures.
  • Subjects who tested positive at screening for HIV, HbsAg or HCV.
  • Subjects whose PR interval is >200 msec at screening and prior to dosing.
  • Subjects whose QTc interval is >450 msec at screening and prior to dosing.
  • Subjects who have used any drugs or substances known to be strong inhibitors of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
  • Subjects who have used any drugs or substances known to be strong inducers of CYP enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first dose.
  • Subjects who have been on a special diet (for whatever reason) during the 28 days prior to the first dose and throughout the study.
  • Subjects who, through completion of the stUdy, would have donated in excess of:

    500 mL of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year.

  • Subjects who have participated in another clinical trial within 28 days prior to the first dose.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01372306


Sponsors and Collaborators
Dr. Reddy's Laboratories Limited
Investigators
Principal Investigator: Gaerano Morelli Early Clinical Research
  More Information

Responsible Party: Assistant Manager - Research & Development, Dr. Reddy's Laboratories Limited
ClinicalTrials.gov Identifier: NCT01372306     History of Changes
Other Study ID Numbers: AA21897
First Submitted: January 27, 2011
First Posted: June 13, 2011
Last Update Posted: June 30, 2011
Last Verified: October 2004

Additional relevant MeSH terms:
Galantamine
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Parasympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Nootropic Agents